R BENITEC
`BIOP
`ARM}!
`1
`er cu.‘ ‘due: I.. I":-
`
`_
`
`O.
`
`h_
`E ..
`
`_
`II.'.--:
`..1 m..r;_;,,g
`-45"‘-'
`
`TECI-l|‘iOLDG‘l‘
`
`3|1‘fl'-|v:E
`
`El-lTE|J.E|I.'|'|J.°.L PROPERTY
`
`l|'INE§'l'0RCE|'l«'TRE
`
`ABOUTUS
`
`NEWSJREDURCE
`
`CONTACFU5
`
`Licensing Options
`
`How to license ddRNAi
`
`Potential to block 22,000+ human-genes
`and Infectious disease gene:
`
`
`
`A
`
`PFELHE
`
`'
`
`-
`
`In-hnuse Programs
`
`|.ice-use-ti Programs
`
`I.iI:enfirgGpI|:'Iu-rls
`
`3 Farmers
`
`I'1a:s:Lr'
`
`Updates
`-fi ‘ r" H’!
`flu-p I.Jpwi'fl1 pwzramccmflyn
`leg-D111, fll'IfM'.||.l|'IDE'lI'ErIl.'l-I evenrsnnd
`mare. Chnosel-iIl'IatyD1.rw¢:1I..
`
`Cunraljsé E1‘
`
`m.m,,u..m.,m_
`|in:nelnq'. pamri-cl-ingmd unre-
`Call r.Irrrr|n:'d'us..
`
`lurin. breast llvsr
`
`-csriaeira
`
`cmrullnrvw:-iIr.a:1I-ml
`
`‘
`
`I‘.
`1
`
`2'-
`
`. Neurological diseases
`nunungaans. darnsalls.
`nlinnbeaslurua
`
`‘. Ininctiops dlsuasslrs
`nwwne, Hap E. Help :1, ‘rs
`
`_ _ ' Auboinmwm diseases
`Rmumguu amuins
`
`Outer dlsaasqa
`Du-manrae rmracirsrmmocllw.
`
`Our genesilen-i:ir:g pla1:fcu'rr1 technology can be iicensedtn develop therapdvsfar multiple human diseases
`induding cancers. neurological diseases, irirfectinus diseasa, autoimmune diseases and |'l"iB|'l_'f urher
`diseases and cnnditinrrs. Target-ape-cific ea-:cl1.|fi'\-e and rlonen-odL|sive iicensfiare available for a broad
`range ufgenetargects. CC‘|'|l:i-E‘.
`
`License our in-house pipeline programs
`Benrbec Ea;-h.a|111.a nperalsa a virtual rnodel. conduutingin-lmuae I:l1erapeul'Jc programs by oufiuurdng
`strategic I'.ElI'|'lpD|'IEl'I1E ofnur raearch and development. We have selecned several key human conditions
`wl'u'd'I can demonstrate the e‘f‘fir_aqr and safety ufddflhl.-ii - induding hepatitis C, hepatitis 3, drug n=5is1a.n-t
`lung cancer. wet Age-related Macularfl-e-geI1erariun and more 111515 IZCII1-E|lI.'lCl<'|:S-3!“1a'lfl2\J'iablE delivery
`upticlns. high cnrnrnerlzial 1:-mnenrial and realistic regulatory pa1:I1way_=.
`
`Our plan is 1.13 progress uurin-I10-use therapeutic pn:-grai1'Is tn proofufconcept smdifi. Phase I and II trials
`before seekingm license the prngrarnsnu pharrnaceufical cornpania. C'.1I'~'.a-I:r Us
`
`Partner and!-or ccrdevelop
`We also invite opparmnilifi to leverage our ddFiN.-°.i p|a1fan'n tedmnlogy fora wide range ufmerapeufifi.
`viajairItvern1:rI=5 with biubech and pharrna curnpaniaes.
`
`Co-developrnent inquiria are welcomed from groups with an interest in taking an earlyoptinn on one or
`more ofour in-house pmgrarns. Cents: <'.Es
`
`Access our research tools
`
`We are also rncInetizia1gdclRNA.E tedlrbnlogp in 1:I1e fcinn of research ‘DDCHS which are available through
`bechnoingr licensing Ccntstz '.Js
`
`TECI-1|'\l0F_0GY
`Whatisddflhlh?
`Whatis R1’-IA?
`siRN.A\-s 5hRv_'-M
`Publiisliuris
`Science Glussary
`
`lNTELL£C[i.|..li_ nnomnrv
`“WWW
`BEHWBE 9359313
`Licensed Pmervls
`'T1'aderna'k:
`
`PJPELINE
`In-house pmgfirns
`licensed pragrarns_
`Linensirignprriau-ns
`Partners
`
`ABGUT U5
`our shnry.
`Manafiefnm
`30341‘
`Curpurate D'u'ecu:Iry
`
`l|'W'El'DR CENTRE
`Whgrlnvest in Eenhnec?
`Stucklnfn
`Afiilknnuunuemems
`Email Updates
`Frfiematiurts
`Janalyst Coverage
`Repum
`lmesmr Fact Sheet
`Sl1areh-nl:§er Meetings
`Jmfinrfiga
`“3R -‘nadi-E
`Giwernanae
`
`Blown-
`in: Int!
`lJ§}:1iiT-i.':'.
`
`ENITEC
`Gt IIuih
`GP‘!-I.A.fi.M.I\
`.-.H ,..... nu ....
`Benilecflfiullharma
`1-15 Barrst
`Ba|mainl;S_-.I1:h1ef|
`MSW .i'u.|stIalia
`F. +61 29555 6985
`E-_irrfu@heri1:ecr_om
`
`<3 2:lJl5.All Eights ReEser\ved.Bvu1ilzecEiopl1arrnaL§1r:‘i!ed
`mung :r.ue1-rams seraa.soptwm|_r.&:i.-‘granular Li[e®.Tr1l:net.nl’11.ID.l-Ia?hsn"rn.bO.Mem.arr\:!O
`
`fiiin
`
`CSHL EXHIBIT 2017
`BENITEC V. CSHL
`IPR2016-00016
`Privacy Policy : Terms i:rl’Use